Malaria vaccines in development.
The recent infusion of public and private funding for malaria vaccine development has greatly accelerated the pace at which candidate malaria vaccines are entering the clinic. Recent promising results from vaccine trials carried out in malaria-naive and -endemic populations have revealed important insights into what will be required of a successful vaccine. Significant challenges lie ahead, not the least of which is insuring access of a malaria vaccine to the populations that need it most. Creative strategies, strong partnerships with developing countries, industry-like approaches to product development, and political vision and leadership on the part of wealthy nations will be critical to the successful implementation of this important new tool to reduce the intolerable burden of malaria.
Ballou
W Ripley
WR
Clinical Research and Development, GlaxoSmithKline Biologicals, Rixensart, Belgium. ballouw@medlmmune.com
D000818:Animals; D002986:Clinical Trials as Topic / Q000639:trends; D004345:Drug Industry / Q000639:trends*; D014943:Global Health; D006801:Humans; D008288:Malaria / Q000276:immunology / Q000517:prevention & control*; D017780:Malaria Vaccines / Q000627:therapeutic use*; D010963:Plasmodium falciparum / Q000276:immunology*
D017780:Malaria Vaccines